Background Regular use of inhaled corticosteroids (ICS) in patients with obstructive lung
diseases has been associated with a higher risk of pneumonia, particularly in COPD. The …

Recent studies have suggested that inhaled corticosteroids (ICS) may be associated with
higher risks of tuberculosis and pneumonia in patients with COPD. However, it is not known …

Background Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for
chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β2 …

Rationale: Previous use of inhaled corticosteroids (ICS) in patients with chronic obstructive
pulmonary disease has been associated with increased risk of community-acquired …

Real-world data provide the potential for generating evidence on drug treatment effects in
groups excluded from trials, but rigorous, validated methodology for doing so is lacking. We …

INTRODUCTION: The use of inhaled corticosteroids (ICS) in COPD may be associated with
an increased risk of pneumonia. Little is known of this risk in newly diagnosed COPD …

Introduction Observational studies using case-control designs have showed an increased
risk of pneumonia associated with inhaled corticosteroid (ICS)-containing medications in …

Asthma and COPD are defined as different disease entities, but in practice patients often
show features of both diseases making it challenging for primary care clinicians to establish …

Background Early descriptions of the coronavirus outbreak showed a lower prevalence of
asthma and COPD than was expected for people diagnosed with COVID-19, leading to …

Patients with chronic obstructive pulmonary disease (COPD) have higher incidence and
prevalence of other chronic inflammatory diseases, including inflammatory bowel disease …